This company listing is no longer active
Abliva (ABLIS) Stock Overview
Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ABLIS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Abliva AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.33 |
| 52 Week High | SEK 0.33 |
| 52 Week Low | SEK 0.33 |
| Beta | 1.16 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -58.42% |
| 5 Year Change | -85.56% |
| Change since IPO | -93.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABLIS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | 0.9% |
| 1Y | n/a | 37.7% | 20.5% |
Return vs Industry: Insufficient data to determine how ABLIS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how ABLIS performed against the UK Market.
Price Volatility
| ABLIS volatility | |
|---|---|
| ABLIS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: ABLIS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ABLIS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 7 | Ellen Donnelly | abliva.com |
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children’s Hospital of Philadelphia, and Oroboros Instruments.
Abliva AB (publ) Fundamentals Summary
| ABLIS fundamental statistics | |
|---|---|
| Market cap | SEK 240.31m |
| Earnings (TTM) | -SEK 85.26m |
| Revenue (TTM) | SEK 31.00k |
Is ABLIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABLIS income statement (TTM) | |
|---|---|
| Revenue | SEK 31.00k |
| Cost of Revenue | SEK 68.30m |
| Gross Profit | -SEK 68.27m |
| Other Expenses | SEK 17.00m |
| Earnings | -SEK 85.26m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
May 23, 2023
| Earnings per share (EPS) | -0.081 |
| Gross Margin | -220,216.13% |
| Net Profit Margin | -275,038.71% |
| Debt/Equity Ratio | 0% |
How did ABLIS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/15 13:44 |
| End of Day Share Price | 2023/01/16 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abliva AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Patrik Ling | DNB Carnegie |
| Jonas Peciulis | Edison Investment Research |
| Niklas Elmhammer | Redeye |